Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

New adenosine A3 receptor antagonist reported at ACS

Sep. 6, 1996

Potential new treatment for Alzheimer's disease disclosed by SIBIA Neurosciences

Sep. 6, 1996

INSERM and Bioprojet describe a new histamine H3 receptor antagonist

Sep. 6, 1996

Tiagabine clinical data reported at congress this week

Sep. 6, 1996

Fosphenytoin launch imminent

Sep. 6, 1996

Mechanism-based enzyme inhibitor may serve as a lead for new anticonvulsants

Sep. 6, 1996

NS-2389: a potential new antidepressant

Sep. 6, 1996

Reversible MAO inhibitors from Hoechst Marion Roussel

Sep. 6, 1996

Lilly's olanzapine deemed approvable

Sep. 6, 1996

Antipsychotic dopaminergic compounds from E. Merck

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...